Clinical trialNCT04055844CompletedPhase 2Interventional

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

SponsorMasonic Cancer Center, University of MinnesotaEnrollment14Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloid and Monocytic Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Armin Rashidi, MD, PhD
Division of Hematology, Oncology and Transplantation, University of Minnesota
Principal Investigator
clinicaltrials.gov ↗
Eric Huselton, M.D.
University of Rochester
Principal Investigator
clinicaltrials.gov ↗
John F Dipersio, M.D., Ph.D.
Washington University School of Medicine
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Mark A Schroeder, M.D.
Washington University School of Medicine
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
Washington University Medical School
St Louis, Missouri, United States
University of Rochester Medical Center
Rochester, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Decitabine →Donor Lymphocyte InfusionRuxolitinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Feb 2020
Primary completion: 6 Sept 2022
Completion: 6 Sept 2022
Last update posted: 7 Nov 2023
Registered enrollment: 14
Registry id: NCT04055844

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.